Robert Fried

I mean, I feel like that would be fairly easy to test in a mouse model, for example.

Yes, hundreds of them at this point.

The mouse studies have shown that almost every condition related to aging is also associated with a reduced level of NAD across the board.

All tissues, all organs.

And we've shown that in mouse studies and rat studies and pig studies and in dog studies.

And increasingly in human studies.

We've also shown that elevating NAD by giving them something like NR helps either preventing disease or actually in some ways treating disease.

And we're at the somewhat early stages of that in humans.

But we have made some significant progress even in human clinical studies.

Yeah, I mean, before you came in, I did just a brief scan and I saw there were some pilot studies in Parkinson's disease.

There have been others.

Maybe you can speak to that.

Any indication that's related to mitochondrial dysfunction or inflammation sparks our interest, particularly things that are neuroinflammatory.

And increasingly, as you read the material on Parkinson's, people believe that it's mitochondrial, that it's related to mitochondria.

So that's been an area of high emphasis for us.

By the way, Alzheimer's as well, mostly because the dementia is related to neuroinflammation.

But in the case of Parkinson's, we've now published three studies on nicotinamide riboside, which we call Niagen, and Parkinson's.

Now, there were two phase ones and a phase two, and they're mostly about safety.

And one was about a dose response.

we showed that up to 3 grams a day actually had a dose response and was safe.